

Clinical characteristics and mortality risk factors in COVID-19 patients with pulmonary embolism

¹Aysun Şengül¹, ²Yusuf Aydemir¹, ³Derya Özaydın², ⁴Pınar Akın Kabalak², ⁵Yasemin Söyler²,
⁶Hüsnü Baykal³, ⁷Muzaffer Onur Turan⁴, ⁸Ersin Alkılınç⁵, ⁹Fulsen Bozkuş⁶, ¹⁰Pınar Yıldız Gülhan⁷,
¹¹Celal Satıcı⁸, ¹²Sertaç Arslan⁹, ¹³Mustafa Asım Demirkol¹⁰, ¹⁴Nevin Fazlıoğlu¹¹, ¹⁵Aylin Çapraz¹²,
¹⁶Pınar Mutlu¹³, ¹⁷Ülkü Aka Aktürk¹⁰, ¹⁸Nalan Ogan^{*3}

¹Department of Chest Diseases, Faculty of Medicine, Sakarya University, Sakarya, Türkiye

²Department of Chest Diseases, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Türkiye

³Department of Chest Diseases, Ankara Etlik City Hospital, Ankara, Türkiye

⁴Department of Chest Diseases, Faculty of Medicine, İzmir Katip Çelebi University, İzmir, Türkiye

⁵Department of Chest Diseases, Kocaeli City Hospital, Kocaeli, Türkiye

⁶Department of Chest Diseases, Antalya Health Practice and Research Center, Antalya, Türkiye

⁷Department of Chest Diseases, Faculty of Medicine, Düzce University, Düzce, Türkiye

⁸Department of Chest Diseases, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye

⁹Department of Chest Diseases, Acıbadem Ataşehir Hospital, İstanbul, Türkiye

¹⁰Department of Chest Diseases, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Türkiye

¹¹Department of Chest Diseases, Faculty of Medicine, Namık Kemal University, Tekirdağ, Türkiye

¹²Department of Chest Diseases, Faculty of Medicine, Amasya University, Amasya, Türkiye

¹³Department of Chest Diseases, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye

Cite this article: Şengül A, Aydemir Y, Özaydın D, et al. Clinical characteristics and mortality risk factors in COVID-19 patients with pulmonary embolism. *J Pulmonol Intens Care*. 2026;4(4):111-117. doi:10.51271/JOPIC-0090

***Corresponding Author:** Nalan Ogan, nalanogan@gmail.com

Received: 20/07/2026

Accepted: 20/10/2026

Published: 28/10/2026

ABSTRACT

Aims: To evaluate the clinical characteristics, radiological findings, and mortality-related factors in patients with COVID-19-associated pulmonary embolism (PE).

Methods: This multicenter retrospective cohort study analyzed data from 13 tertiary centers and included adult patients with molecularly confirmed SARS-CoV-2 infection and radiologically verified PE.

Results: A total of 112 patients were included (mean age: 59.9±14.1 years), of whom 50% had severe pneumonia. PE and COVID-19 were diagnosed simultaneously in 29.5% of cases. The median interval between COVID-19 diagnosis and PE development was 6 days. Despite standard or intermediate-dose thromboprophylaxis, PE occurred in 42.9% of patients. Computed tomography pulmonary angiography demonstrated predominantly peripheral embolic involvement (58.0%). According to early mortality risk stratification, 5.4% of patients were classified as high risk and 19.6% as intermediate-high risk. The in-hospital and 30-day mortality rates were 7.1% and 12.5%, respectively. Mortality was significantly associated with advanced age, comorbidities, severe pneumonia, thrombocytopenia, elevated lactate dehydrogenase and ferritin levels, high/intermediate-high risk classification, intensive care unit admission, and invasive mechanical ventilation. Multivariate logistic regression identified thrombocytopenia as an independent predictor of 30-day mortality (OR 10.11, 95% CI 1.49-68.92; p=0.01).

Conclusion: PE commonly develops during the early phase of COVID-19 and may occur despite thromboprophylaxis. Early recognition and individualized risk-adapted.

Keywords: COVID-19, pulmonary embolism, biomarkers, thrombosis, mortality

INTRODUCTION

The emergence of Coronavirus Disease 2019 (COVID-19) in early 2020 precipitated an unprecedented global health crisis marked by rapid transmissibility and considerable mortality worldwide.¹ Beyond its primary respiratory manifestations, COVID-19 has been increasingly recognized as a multisystem disorder associated with significant thromboinflammatory complications. In particular, critically ill patients demonstrate a markedly increased predisposition

to venous thromboembolism (VTE). Growing clinical evidence has consistently shown that disease severity is strongly associated with an elevated risk of acute thrombotic events, including pulmonary embolism (PE) and deep vein thrombosis.²⁻⁴

The pathophysiological mechanisms underlying VTE in COVID-19 are complex and multifactorial, encompassing



all major components of Virchow's triad: endothelial injury, hypercoagulability, and circulatory stasis. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly infects vascular endothelial cells, leading to diffuse endothelial dysfunction and promoting both localized and systemic thrombotic responses.⁵ The accompanying inflammatory and procoagulant state is characterized by elevated levels of fibrinogen, fibrin degradation products, fibrin, and D-dimer. In addition, direct viral cytopathic injury together with an exaggerated cytokine-mediated inflammatory response is believed to trigger pathological platelet activation, further amplifying the underlying coagulopathic process.^{6,7} Prolonged immobilization, particularly among critically ill and intensive care unit patients, contributes to venous stasis and further increases thrombotic risk, thereby completing the classical prothrombotic framework described by Virchow's triad.

Histopathological examinations and autopsy studies of patients who died from COVID-19 have consistently demonstrated a high prevalence of diffuse pulmonary microthrombi.⁸ These pathological findings have led to the growing recognition that the development of acute respiratory distress syndrome (ARDS), the most severe and life-threatening manifestation of COVID-19, is closely linked to profound pulmonary endothelial injury and dysregulated intravascular coagulation. Accordingly, the pulmonary vascular pathology observed in severe COVID-19 is increasingly considered distinct from classical ARDS and has been described as pulmonary intravascular coagulopathy (PIC) or localized pulmonary thrombosis.^{9,10}

This concept is further supported by clinical evidence demonstrating that the incidence of PE in patients with COVID-19 exceeds that of concomitant deep vein thrombosis (DVT).¹¹ This epidemiological pattern suggests that thrombotic events associated with COVID-19 may differ from the traditional thromboembolic pathway of systemic VTE and instead reflect a process of in situ pulmonary immunothrombosis within the pulmonary vasculature. Collectively, these findings contribute to a better understanding of the distinct pathophysiology underlying COVID-19-associated ARDS and may guide the development of targeted therapeutic strategies aimed at mitigating the localized thromboinflammatory response.

Clinical studies evaluating COVID-19 patients with thromboembolic complications have consistently demonstrated a strong association between PE and increased mortality.¹² These findings suggest that thrombotic events contribute substantially to disease progression and adverse clinical outcomes, highlighting the critical importance of early recognition and appropriate anticoagulation strategies in high-risk patients. Consequently, several national and international guidelines recommend routine pharmacological VTE prophylaxis for hospitalized patients with COVID-19, particularly in those with severe disease or additional thrombotic risk factors.¹³ These recommendations are supported by accumulating evidence indicating that thrombotic risk increases in parallel with the severity of respiratory failure, emphasizing the central role of optimized antithrombotic management in reducing VTE-related morbidity and improving survival.

Nevertheless, despite the widespread adoption of standardized thromboprophylaxis protocols, acute PE remains a frequent, severe, and potentially fatal complication of COVID-19. Although existing studies have associated PE with increased mortality, detailed evidence delineating the specific demographic, biochemical, and clinical profiles that predispose patients to thromboembolic deterioration remains limited. Moreover, there is a relative paucity of data specifically addressing multivariable predictors of mortality within this distinct co-pathological population.

To address this gap, the present study was designed to provide a comprehensive, multidimensional assessment of the clinical characteristics of patients with COVID-19 pneumonia complicated by radiologically confirmed PE. The primary aim was to identify independent determinants of adverse outcomes through systematic evaluation of baseline demographic features, laboratory parameters, and indicators of disease severity. This approach seeks to enhance current understanding of the prognostic significance of PE in COVID-19 and to inform more precise, risk-adapted therapeutic strategies aimed at improving survival.

METHODS

This study was conducted with the approval of the Non-interventional Ethics Committee of Sakarya University (Date: 29.01.2021, Decision No: E-71522473-050.01.04-6095). All procedures were carried out in accordance with the ethical rules and the principles of the Declaration of Helsinki.

This multicenter retrospective cohort study pooled data from 13 tertiary medical centers following approval by the national Ministry of Health and the administrative boards of all participating institutions. The study included adult patients with real-time polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infection who developed acute PE either at initial presentation or within 45 days of COVID-19 diagnosis, between April 1, 2020, and February 1, 2021. Pediatric patients (<18 years), pregnant individuals, and those with a prior history of thromboembolic disease were excluded from the analysis. The 45-day interval was selected as a predefined inclusion window to capture PE events occurring during the acute and early post-acute phases of COVID-19. The requirement for written informed consent was waived by the Institutional Review Board due to the retrospective nature of the study. A diagnosis of COVID-19 was established based on positive real-time polymerase chain reaction (RT-PCR) results obtained from oro-nasopharyngeal swab samples, in conjunction with compatible clinical manifestations and characteristic radiological findings consistent with viral pneumonia. The definitive diagnosis of pulmonary thromboembolism (PE) was confirmed exclusively by computed tomography pulmonary angiography (CTPA). This imaging modality was performed in patients presenting with clinical suspicion of thromboembolic disease at hospital admission or in those who developed unexplained acute cardiopulmonary deterioration during hospitalization. This diagnostic approach enabled accurate and comprehensive characterization of both the primary viral infection and secondary thromboembolic complications. Electronic medical records and paper-based files were systematically reviewed to collect data on demographic characteristics,

clinical features, laboratory parameters, radiological findings, therapeutic interventions, and survival outcomes.

In accordance with national COVID-19 management guidelines issued by the Ministry of Health, pharmacological thromboprophylaxis in patients with severe disease consisted of low-molecular-weight heparin (LMWH; enoxaparin 40 mg subcutaneously twice daily) or unfractionated heparin (UFH; 7,500 U subcutaneously twice daily). In patients with non-severe disease, standard prophylaxis was administered as enoxaparin 40 mg subcutaneously once daily.¹³

Risk stratification for PE severity and assessment of early mortality risk (defined as in-hospital or 30-day all-cause mortality) were performed in accordance with the 2019 European Society of Cardiology/European Respiratory Society (ESC/ERS) Guidelines for the diagnosis and management of acute PE. The primary outcome was 30-day all-cause mortality, defined as death from any cause within 30 days of PE diagnosis, with the date of diagnosis serving as the starting point for follow-up. Clinical severity of COVID-19 pneumonia was classified according to national protocols; severe disease was defined as peripheral oxygen saturation (SpO₂) ≤90% on room air, respiratory rate >30 breaths per minute, and radiological evidence of bilateral diffuse pulmonary infiltrates.¹⁴ Secondary macrophage activation syndrome (MAS) was diagnosed after exclusion of bacterial superinfection, based on a characteristic clinical and laboratory constellation including persistent fever, markedly elevated C-reactive protein (CRP), serum ferritin levels exceeding 700 µg/L, increased D-dimer concentrations, absolute lymphopenia, thrombocytopenia, relative neutrophilia, and progressive hepatic dysfunction. Baseline laboratory parameters were obtained from the measurements recorded at the time of PE diagnosis. For baseline laboratory definitions, absolute lymphopenia was defined as a lymphocyte count <800/µL, while thrombocytopenia was defined as a platelet count <150×10⁹/L. Pathological elevations in lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), ferritin, blood urea nitrogen, and creatinine were defined as values exceeding the upper limits of normal according to the reference ranges of the local laboratory.

Statistical Analysis

Data management and statistical analyses were performed using SPSS software (version 20.0; IBM Corp., Armonk, NY, USA). Descriptive statistics were used to summarize the study variables. Categorical variables were expressed as frequencies and percentages, whereas continuous variables were presented as mean±standard deviation (SD) or median, as appropriate. Comparisons of categorical variables between groups were conducted using the Chi-square test. The normality of continuous variables was assessed using the Shapiro-Wilk test. For non-normally distributed variables, between-group comparisons were performed using the Mann-Whitney U test. Variables that demonstrated statistical significance in univariate analyses were subsequently entered into multivariate regression models to identify independent predictors of mortality. Multivariable logistic regression analysis was performed to evaluate factors associated with 30-day all-cause mortality. The model included six variables: age, comorbidity status, lymphopenia, thrombocytopenia, ferritin, and LDH. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. Given the limited number of mortality events (n=14) relative to the number of variables included, the regression findings were interpreted cautiously because of the potential risk of overfitting. A two-tailed p-value <0.05 was considered statistically significant. This analytical approach provided a robust framework for evaluating prognostic determinants of survival in the study population.

RESULTS

During the study period, acute PE was radiologically confirmed in 112 patients with COVID-19. Of these, 74 (66%) were male and 38 (34%) were female, with a mean age of 59.9±14 years. A severe pneumonia phenotype was present in 56 patients (50%), while secondary MAS was identified in 18 patients (16.1%). Detailed baseline demographic, clinical, and biochemical characteristics are presented in **Table 1**.

The mean interval between COVID-19 diagnosis and PE detection was 8.8±9.4 days, with a median of 6 days. Synchronous presentation of COVID-19 pneumonia and PE at admission was observed in 33 patients (29.5%). Notably,

Table 1. Clinical features of patients with COVID-19 pneumonia complicated by pulmonary embolism

	Total (n= 112)	No mortality (n=98)	Mortality (n=14)	p
Age (n, years)	59.9 (±14.1)	58.9 (±14.1)	67.3 (±12.0)	0.039*
Male gender (n,%)	74 (66%)	64 (65.3%)	10 (71.4%)	0.769
Occurrence day of embolism (±SD)	8.8 (±9.4)	9.0 (±9.8)	7.14 (±5.9)	0.986
Concurrent embolism diagnosis with COVID-19 (n,%)	33 (29.4%)	31 (31.6%)	2 (14.3%)	0.226
Presence of additional disease (n,%)	68 (60.7%)	56 (57.1%)	12 (85.7%)	0.041*
Presence of severe pneumonia (n,%)	56 (50%)	44 (44.9%)	12 (85.7%)	0.004*
Multiple pneumonia focus at CT (n,%)	94 (83.9%)	81 (82.7%)	13 (92.9%)	0.461
MAS diagnosis (n,%)	18 (16%)	14 (14.3%)	4 (28.6%)	0.236
Steroid use (n,%)	51 (45.5%)	42 (42.9%)	9 (64.3%)	0.132
High and moderate-high risk of early mortality from pulmonary embolism (n,%)	28 (25%)	17 (17.3%)	11 (78.6%)	0.000*
Thrombolytic use (n,%)	7 (6.3%)	3 (3%)	4 (28.6%)	0.004*
Intensive care hospitalization (n,%)	26 (23.2%)	17 (17.3%)	9 (64.3%)	0.01*
Intubation requirement (n,%)	11 (9.8%)	2 (2%)	9 (64.3%)	0.000*

*p<0.05. SD: Standard deviation, CT: Computed Tomography, MAS: Macrophage activation syndrome

PE developed despite standard thromboprophylaxis in 48 patients (42.9%). CTPA revealed predominantly peripheral embolic involvement (segmental or subsegmental, unilateral or bilateral) in 65 patients (58%). According to early mortality risk stratification, 6 patients (5.4%) were classified as high risk, 22 (19.6%) as intermediate-high risk, 24 (21.4%) as intermediate-low risk, and 60 (53.6%) as low risk. Anticoagulation therapy included low-molecular-weight heparin in 88 patients (78.6%), unfractionated heparin in 16 (14.3%), and direct oral anticoagulants in 8 (7.1%). Systemic thrombolysis was administered to 7 patients. Minor bleeding occurred in one patient, while major bleeding was observed in two, including one case following thrombolysis. Intensive care unit admission was required in 26 patients, and 11 patients underwent invasive mechanical ventilation. In-hospital mortality was 7.1% (n=8), while 30-day all-cause mortality was 12.5% (n=14). Exploratory analyses identified advanced age, comorbidities, severe pneumonia, thrombocytopenia, elevated LDH and ferritin levels, higher early mortality risk class, thrombolysis, ICU admission, and mechanical ventilation as significant correlates of 30-day mortality. Although D-dimer levels were higher in non-survivors, the difference was not statistically significant (p=0.33). Similarly, CRP levels, acute renal dysfunction, and hepatic impairment were not significantly associated with mortality (Table 2).

The multivariable logistic regression model included age, comorbidity status, lymphopenia, thrombocytopenia, ferritin, and LDH. Thrombocytopenia was significantly associated with 30-day mortality (OR 10.11, 95% CI 1.485-68.916; p=0.01). In contrast, age (p=0.14), comorbidity status (p=0.99), lymphopenia (p=0.72), ferritin (p=0.82), and LDH (p=0.29) were not significantly associated with mortality in the multivariable model.

DISCUSSION

The present investigation focused on the clinical trajectories of patients with COVID-19 pneumonia who concurrently manifested acute PE, demonstrating an in-hospital mortality rate of 7.1% and an overall 30-day mortality rate of 12.5%. Survival deficits within this cohort were significantly linked to advanced age, preexisting comorbid burdens, severe pneumonia phenotypes, absolute thrombocytopenia, and pathological elevations in serum LDH and ferritin concentrations. Additionally, adverse outcomes closely

correlated with high or intermediate-high early mortality risk classifications, the administration of systemic thrombolysis, intensive care unit escalation, and the requirement for endotracheal intubation.

When contextualized within the regional literature, a large-scale study examining 1,500 hospitalized COVID-19 patients in Türkiye documented a baseline in-hospital mortality rate of 4.5%.¹⁵ In contrast, specific evaluations restricted to COVID-19 pneumonia populations complicated by PE reported a higher in-hospital mortality rate of 8.7%, while a broad meta-analysis estimated pooled mortality figures as high as 45.1% among co-pathological cohorts.^{16,17} The survival data from our study occupies an intermediate position; the recorded mortality was expectedly higher than that traditionally observed in isolated COVID-19 pneumonia lacking embolic complications, yet it remained notably lower than the fatality rates frequently described in historical datasets for COVID-19 patients suffering from concurrent PE.

In exactly 33 instances, acute PE was identified synchronously alongside the initial presentation of COVID-19, underscoring the immediate and aggressive thrombotic drive characterizing this viral syndrome. The temporal analysis showed that the mean interval spanning from the initial molecular detection of COVID-19 to the objective confirmation of PE was 8.8 days, with a median onset occurring at the 6-day mark. Crucially, embolic breakthroughs manifested in 42.9% of our patients despite the active administration of standard-dose or intermediate-dose LMWH prophylaxis, illustrating the profound clinical difficulties encountered when attempting to suppress the hypercoagulable state in this population.

While a consensus across multiple national and international clinical guidelines rigorously dictates the universal implementation of pharmacological thromboprophylaxis for hospitalized COVID-19 pneumonia patients to reduce VTE-driven morbidity,^{13,18-22} thromboembolic failures persist as a major clinical hurdle. This vulnerability is especially pronounced among critically ill individuals, in whom an intense systemic inflammatory response and secondary hypercoagulability frequently override conventional prophylactic measures.²¹ Supporting this observation, a comprehensive meta-analysis focusing on PE epidemiology during the pandemic documented a pooled prevalence of 18.6% among patients managed with standard

Table 2. Laboratory parameters in COVID-19 pneumonia patients with pulmonary embolism

	Total		No mortality		Mortality		p
	n		n		n		
D-dimer level during embolism (µg/L)	101	4408.2(±5443)	89	4027.5(±4950)	12	7231.6(±7967)	0.337
CRP level (n/ mg/L)	109	82.2(±71.3)	95	80.1(±72.9)	14	96.8(±59.2)	0.182
Lymphopenia (n,%)	106	24 (22.6%)	92	20 (21.7%)	14	4 (28.6%)	0.516
Thrombocytopenia (n,%)	112	17 (15.2%)	98	12 (12.2%)	14	5 (35.7%)	0.038*
High ferritin level (n,%)	101	51 (50.5%)	87	40 (46%)	14	11 (78.6%)	0.024*
High LDH level (n,%)	93	66 (71%)	82	57 (69.5%)	11	11 (100%)	0.033*
Liver dysfunction (n,%)	111	29 (26.1%)	93	24 (25.8%)	14	5 (35.7%)	0.521
Kidney dysfunction (n,%)	112	18 (16%)	98	14 (14.3%)	14	4 (28.6%)	0.236

*p<0.05. D-dimer: Fibrin degradation product, CRP: C-reactive protein, Lymphopenia: Decreased lymphocyte count, Thrombocytopenia: Decreased platelet count, Ferritin: Iron-storage protein, LDH: Lactate dehydrogenase

thromboprophylaxis, which altered minimally to 17.3% in cohorts receiving mixed-dose prophylactic strategies.¹²

Although escalating to intermediate-dose antithrombotic regimens succeeds in lowering overall VTE incidence, it concurrently inflates the hazard of hemorrhagic complications. This trade-off was highlighted in another meta-analysis that reported a 3.9% incidence of major bleeding events, noting that both moderate and full-intensity therapeutic dosing schemes were independently tied to escalated bleeding risks.²² Collectively, these dual risks underscore the intricate therapeutic tightrope clinicians must walk when managing COVID-19-associated coagulopathy. Refining preventative antithrombotic frameworks thus demands a highly individualized approach that carefully balances a patient's baseline thrombotic predisposition against their specific hemorrhagic risks, factoring in acute physiological severity and emerging clinical trial data. Consequently, prospective investigations remain vital to establishing optimized prophylactic dosing architectures capable of suppressing embolic breakthroughs without inducing prohibitive bleeding penalties.

The development of severe pneumonia and subsequent hypoxemic respiratory failure are profoundly coupled with escalated mortality rates in the context of COVID-19.²³ Consistent with this pathophysiological link, Jevnikar and colleagues²⁴ identified a heightened frequency of acute PE episodes specifically among individuals presenting with severe hypoxemia. In perfect agreement, our data demonstrates that patients suffering from severe pneumonia experienced significantly higher mortality rates, a clinical decline predominantly driven by profound hypoxemic insult rather than the literal geometric extent of radiological involvement, which failed to demonstrate a significant association with survival outcomes.

Biochemical monitoring within our complete cohort revealed an overall mean D-dimer concentration of 4.408 µg/L, which escalated to a mean of 7.231 µg/L among the deceased subset. For context, historical datasets have reported distinct D-dimer profiles, showcasing means of 3.519 µg/L in patients with confirmed PE compared to 1.371 µg/L in those free of embolic complications.¹⁶ The clinical utility of up-regulated D-dimer magnitudes as a primary predictor of elevated VTE risk during COVID-19 is well-established; notably, Cui et al.³ determined that a biomarker threshold of 1.500 µg/L yielded a sensitivity of 85% and a specificity of 88.5% when forecasting VTE among critically ill individuals in intensive care units. Furthermore, from the inception of the pandemic, marked D-dimer elevations have served as an adverse prognostic signature, with circulating concentrations exceeding 1.0 mg/L independently tied to an 18-fold increase in individual mortality risk.^{1,25} Within our current investigation, although the nonsurvivors exhibited substantially higher absolute D-dimer values than survivors, this mathematical divergence did not cross the threshold for formal statistical significance.

Regarding the anatomical distribution of the vascular occlusions, peripheral emboli were documented in 58% of our study population. A systematic review and meta-analysis of 26 studies involving 4,382 hospitalized patients with COVID-19 reported pooled incidences of peripheral and central pulmonary embolism of 12.3% and 6.8%, respectively.¹²

Prognostic indicators significantly tied to fatal outcomes within our cohort encompassed advanced age, preexisting comorbid conditions, severe pneumonia phenotypes, absolute thrombocytopenia, and pathological elevations in circulating LDH and ferritin. Additionally, markers of acute physiological stress, such as high or intermediate-high early mortality risk classifications, intensive care unit escalation, and the requirement for endotracheal intubation, were powerful correlates of mortality. To date, there remains a distinct void in the literature systematically tracking the multivariable determinants of mortality exclusively within a COVID-19 cohort complicated by acute PE. In our study, thrombocytopenia was significantly associated with 30-day mortality in the original multivariable logistic regression analysis. However, the limited number of mortality events (n=14) raises concerns regarding potential overfitting and the stability of this estimate. Thrombocytopenia may reflect the severity of the underlying COVID-19 infection rather than represent an independent prognostic factor specifically associated with pulmonary embolism. Previous evidence has demonstrated a significant association between thrombocytopenia and severe COVID-19, supporting this interpretation.²⁶ Larger prospective studies are needed to clarify its potential role in mortality risk assessment among patients with COVID-19-associated pulmonary embolism.

Nevertheless, historical data exploring non-selected COVID-19 cohorts has broadly validated advanced age, comorbid burdens, profound hypoxemia, thrombocytopenia, and upregulated D-dimer and LDH concentrations as independent predictors of clinical demise.^{27,28} Parallel to this, classical epidemiological research focusing on PE-related mortality outside the context of SARS-CoV-2 infection has consistently demonstrated a strong survival deficit linked to male gender, advanced age, underlying chronic illnesses, elevated D-dimer levels, acute renal impairment, and high early mortality risk stratifications.²⁹⁻³¹

Collectively, these overlapping clinical architectures highlight the highly complex, multifactorial nature of mortality risks within this specific co-pathological patient population. These insights strongly emphasize the critical necessity for heightened clinical vigilance, intensive biomarkers surveillance, and highly individualized, survival-directed therapeutic strategies designed to optimize patient outcomes.

Limitations

The present study has several limitations that should be acknowledged. Owing to its retrospective cohort design, the analysis is inherently subject to missing or incomplete clinical and laboratory data within electronic medical records, which may limit the granularity and completeness of the findings. In addition, the substantial overlap in clinical manifestations between severe COVID-19 pneumonia and acute PE may have introduced diagnostic challenges, potentially leading to under-recognition of embolic events, particularly in less severely ill patients who did not undergo routine or systematic imaging evaluation. Because our study included only patients with confirmed COVID-19-associated pulmonary embolism, the incidence or prevalence of PE in the overall COVID-19 population could not be determined. Furthermore, the absence of a comparison group without PE precluded assessment of the independent impact of PE on mortality.

To address these limitations, future prospective studies are warranted. Ideally, such investigations should include well-defined, parallel cohorts of COVID-19 patients with and without confirmed thromboembolic disease to more accurately quantify the independent impact of PE on survival. Furthermore, prospective designs would facilitate a more detailed characterization of the underlying pathophysiological mechanisms driving adverse outcomes in this high-risk population.

CONCLUSION

The majority of acute PE events in this cohort occurred during the early, hyperacute phase of COVID-19 symptom onset. This temporal clustering underscores the need for a high index of clinical suspicion and vigilant monitoring for even subtle signs of thromboembolic disease during this critical period. Importantly, the occurrence of PE despite ongoing thromboprophylaxis in a substantial proportion of patients indicates that standard prophylactic regimens may be insufficient to fully counteract the intense prothrombotic milieu associated with SARS-CoV-2 infection. This highlights the limitations of a uniform anticoagulation strategy in this population.

Given the complex interplay between thrombotic risk and bleeding potential in COVID-19 pneumonia, a more individualized, risk-adapted antithrombotic approach appears warranted. Such strategies may include selective escalation to intermediate or therapeutic-intensity anticoagulation in patients with high-risk clinical and laboratory profiles. Ultimately, close clinical surveillance and dynamic adjustment of anticoagulant therapy are essential to optimize survival while minimizing bleeding complications.

ETHICAL DECLARATIONS

Ethics Committee Approval

This study was conducted with the approval of the Non-interventional Ethics Committee of Sakarya University (Date: 29.01.2021, Decision No: E-71522473-050.01.04-6095).

Informed Consent

As this was a retrospective study, formal written informed consent was not required and was therefore not obtained. This retrospective study used pre-existing anonymized patient data. No additional intervention was performed, and there was no direct patient contact. The study was approved by the Ethics Committee, and the requirement for written informed consent was waived by the ethics committee.

Peer Review Process

This manuscript was subject to external peer review.

Conflict of Interest

The authors declare no conflicts of interest related to this study.

Financial Disclosure

The authors received no financial support for the conduct or publication of this research.

Author Contributions

Concept: AŞ; Design: AŞ, YA, NO; Supervision: AŞ; Resources: AŞ, YA, DÖ, PAK, YS, HB, MOT, EA, FB, PYG, CS, SA, MAD, NF, AÇ, PM, ÜAA; Materials: AŞ, YA; Data Collection and/or Processing: AŞ, YA, DÖ, PAK, YS, HB, MOT, EA, FB, PYG, CS, SA, MAD, NF, AÇ, PM, ÜAA; Analysis and/or Interpretation: AŞ, YA; Literature Review: AŞ, NO; Article Writing: AŞ, NO; Critical Review: AŞ, YA, NO.

Acknowledgments

The manuscript was edited for English language clarity using PaperPal, an AI-assisted tool provided by Editage, India. The authors take full responsibility for the accuracy, integrity, and scientific content of the manuscript.

Editor Note

Nalan Ogan is a member of the Editorial Board of this journal. She was not involved in the editor assignment, reviewer selection, peer review process, or editorial decision for this manuscript. The peer review process was managed independently by another editor.

REFERENCES

1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
2. Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. *Thromb Res*. 2020; 191:148-150. doi:10.1016/j.thromres.2020.04.041
3. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(6):1421-1424. doi:10.1111/jth.14830
4. Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. *Semin Thromb Hemost*. 2020;46(7):763-771. doi:10.1055/s-0040-1715456
5. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5
6. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med*. 2020;58(7): 1116-1120. doi:10.1515/cclm-2020-0188
7. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. *J Am Coll Cardiol*. 2020;75(18):2352-2371. doi:10.1016/j.jacc.2020.03.031
8. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med*. 2020;8(7):681-686. doi:10.1016/S2213-2600(20)30243-5
9. McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. *Lancet Rheumatol*. 2020;2(7):e437-e445. doi:10.1016/S2665-9913(20)30121-1
10. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. *Intensive Care Med*. 2020;46(6):1105-1108. doi:10.1007/s00134-020-06059-6
11. Cattaneo M, Bertinato EM, Biorocchi S, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? *Thromb Haemost*. 2020;120(8):1230-1232. doi:10.1055/s-0040-1712097
12. Liu Y, Cai J, Wang C, Jin J, Qu L. A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019. *J Vasc Surg Venous Lymphat Disord*. 2021;9(5):1099-1111.e6. doi:10.1016/j.jvs.2021.01.012

13. Republic of Türkiye Ministry of Health. COVID-19 (SARS-CoV-2 Infection): Scientific Committee Study-Anticytokine-Anti-inflammatory Treatments, Coagulopathy Management. Published June 1, 2020.
14. Republic of Türkiye Ministry of Health. COVID-19 (SARS-CoV-2 Infection) Guide. Published 2020.
15. Kokturk N, Babayigit C, Kul S, et al. The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. *Respir Med.* 2021;183:106433. doi:10.1016/j.rmed.2021.106433
16. Roncon L, Zuin M, Barco S, et al. Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis. *Eur J Intern Med.* 2020;82:29-37. doi:10.1016/j.ejim.2020.09.006
17. Gonzalez-Fajardo JA, Ansuategui M, Romero C, et al. Mortality of COVID-19 patients with vascular thrombotic complications. *Med Clin (Engl Ed).* 2021;156(3):112-117. doi:10.1016/j.medcle.2020.10.008
18. COVID-19 Treatment Guidelines [Internet]. [cited 2021 Dec 1].
19. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. *Chest.* 2020;158(3):1143-1163. doi:10.1016/j.chest.2020.05.559
20. ASH Guidelines on Use of Anticoagulation in Patients with COVID-19-Hematology.org [Internet]. [cited 2021 Dec 1].
21. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res.* 2020;191:145-147. doi:10.1016/j.thromres.2020.04.013
22. Jiménez D, García-Sánchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. *Chest.* 2021;159(3):1182-1196. doi:10.1016/j.chest.2020.11.005
23. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. *PLoS One.* 2020;15(11):e0241955. doi:10.1371/journal.pone.0241955
24. Jevnikar M, Sanchez O, Humbert M, Parent F. Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment. *Eur Respir J.* 2021;58(2):2101033. doi:10.1183/13993003.01033-2021
25. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
26. Zong X, Gu Y, Yu H, Li Z, Wang Y. Thrombocytopenia is associated with COVID-19 severity and outcome: an updated meta-analysis of 5637 patients with multiple outcomes. *Lab Med.* 2021;52(1):10-15. doi:10.1093/labmed/lmaa067
27. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. *Aging Male.* 2020;23(5):1416-1424. doi:10.1080/13685538.2020.1774748
28. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. *Eur Respir J.* 2020;55(5):2000524. doi:10.1183/13993003.00524-2020
29. Salazar MR, González SE, Regairaz L, et al. Risk factors for COVID-19 mortality: the effect of convalescent plasma administration. *PLoS One.* 2021;16(4):e0250386. doi:10.1371/journal.pone.0250386
30. Nijkeuter M, Söhne M, Tick LW, et al. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. *Chest.* 2007;131(2):517-523. doi:10.1378/chest.05-2799
31. Grau E, Tenías JM, Soto MJ, et al. D-dimer levels correlate with mortality in patients with acute pulmonary embolism: findings from the RIETE registry. *Crit Care Med.* 2007;35(8):1937-1941. doi:10.1097/01.CCM.0000277044.25556.93